Hoechst Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Sanofi

Sanofi-a Ventis Deutschland Gmbh

Sanofi-aventis

Hoechst Marion Roussel Deutschland Gmbh

Joachim Wink

Gerhard Seibert

Susanne Grabley

Axel Zeeck

Michael Kurz

Laszlo Vertesy

Klaus Hutter

Wilhelm Stahl

Burkhard Sachse

Jozsef Aszodi

Peter Braun

Astrid Markus

Luigi Toti

Peter Hammann

Peter Eckes

Carlo Giani

Heinz Hanel

Cordula Hopmann

Jurgen Logemann

Martin Knauf

Jozef Schell

Dominique Le Beller

Norbert Ulbrich

Rolf Hilgenfeld

Wolfgang Raether

Hermann Uhr

Ernold Granzer

Klaus Kuhlein

Herbert Kogler

Dieter Isert

Gunther J Riess

Mark Broenstrup

Hans-Matthias Deger

Irvin Winkler

Hans Guehring

Johannes Meiwes

Rolf Müller

Klaus-ulrich Weithmann

Wulf Dirk Leuschner

Stefan Bartoschek

Matthias Schiell

Johann Gassenhuber

Silke Wenzel

Roderich Suessmuth

Klaus Ehrlich

Susanne Dobreff

Rainer Buchholz

Ralf Thiericke

Roderich Süssmuth

Thomas Bayer

Mark Brönstrup

Holger Hoffmann

Nirogi Venkata Satya Ramakrishna

Albert Haertl

Udo Graefe

Brigitte Schlegel

Ravi Gajanan Bhat

Laszl&oacute; V&eacute;rtesy

Laszio Vertesy

Hélène Olivan

Martin Gerlitz

Cosima Dufour-Schroif

Carsten Volz

Tina Binz

Claudia Koenig

Pia Kricke-Helling

Siegrid Philipps

L&aacute;szl&oacute; Vertesy

Mathias Schiell

László Vertesy

Kathrin Meindl

Elaine A Powers

Francis P Barbone

Elizabeth A Cashman

Gerhard Noelken

Rajendra Prakash Tanpure

Uttara Vinayak Oak

Shantilal Dayaram Naker

Erra Koteswara Satya Vijayakumar

Eyyammadichiyil Sankaranarayanan Sreekumar

George M Sheldrick

Martin Albert Knauf

Heike Stump

J&uuml;rgen Backhaus

László Vértesy

Timo Schmiederer

Caudia Koenig

Rolf Mueller

Joanna Krawczyk

George Sheldrick

Lászlo Vertesy

The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.

Gene cluster for biosynthesis of griselimycin and methylgriselimycin

The invention relates to streptospirole derivatives of the general formula (I), wherein R, R, R, X, X, Yand Yare as defined herein, a process for the preparation of said compounds by fermenting the microorganismsp. ST 108140 (DSM 19369) and optionally derivatizing the compounds produced by said microorganism, a pharmaceutical composition comprising at least one compound of the formula (I), and the use of a compound of the formula (I) for the preparation of a medicament for the treatment and/or prophylaxis of bacterial infections. 

Streptospirole derivatives

The disclosure relates to a compound of the formula (I) wherein

[object Object]

The invention relates to the use of a compound of the formula (I) for the treatment of bacterial infections caused by mycobacteria, nocardia or corynebacteria, wherein E is phosphorus; X, Xand Xare oxygen; and Rand Rare as defined in the specification.

Use of cyclipostin derivatives for the treatment of mycobacterial infectious diseases

The present invention relates to novel compounds, termed serpentemycins, of the formula (I) in which Y, R, R, R, R, X, X, X, n, m and o are as defined in the specification, which are formed by the microorganismsp. DSM 14865 during its fermentation, to chemical derivatives of the serpentemycins, to a process for preparing them, and to their use as pharmaceuticals, in particular for the treatment and prophylaxis of infectious bacterial diseases.

Polyenecarboxylic acid derivatives, processes for preparing them, and their use

Embodiments of the present invention relate to administering cephaibols to treat conditions of the nervous system and to treat those conditions in which suppressing the immune system would have beneficial effect.

Method for treating neurological conditions and inducing immunosuppression with cephaibols

The present invention relates to novel active compounds named Citrullimycines, which are obtainable by cultivation ofsp. ST 101396 (DSM 13309), and to their pharmaceutically acceptable salts and derivatives. The present invention further relates to a process for the production of the Citrullimycines, to the microorganismsp. ST 101396 (DSM 13309), to the use of the Citrullimycines and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, for example as inhibitors of the neurotensin receptor, and to pharmaceutical compositions comprising Citrullimycines or a pharmaceutically acceptable salt or derivative thereof.

Citrullimycines, a process for their production and their use as pharmaceuticals

Cyclipostins, process for their preparation and use thereof

Pluraflavins and derivatives thereof, process for their preparation and use thereof

New active agents (ustilipides) formed by the microorganism Ustilago maydis, FH 2634, DSM 11494 during fermentation. The invention also relates to a method for the production of said ustilipides and to their use as medicaments in the treatment of schizophrenia or diseases caused by dopamine metabolic dysfunction. The invention further relates to medicaments containing ustilipides and to the microorganism Ustilago maydis, FH 2634, DSM 11494.

Ustilipides, method for the production and the use thereof

The present invention relates to a compound named Vancoresmycin which is obtainable by cultivation of the microorganism HIL-006734 (DSM 12216), and to its pharmaceutically acceptable salts. The present invention further relates to a process for the production of Vancoresmycin, to the microorganism HIL-006734 (DSM 12216), to the use of Vancoresmycin and its pharmaceutically acceptable salts as pharmaceuticals, and in particular to their use as antibiotics, and to pharmaceutical compositions comprising Vancoresmycin or a pharmaceutically acceptable salt thereof.

Vancoresmycin, a process for its production and its use as a pharmaceutical

Stromelysin inhibitors

Antifungal peptides from scleroderma texense

The invention relates to lipopeptides with very homologous amino-acid sequences but different fatty acid residues (lipid portion) which are synthesized by Actinoplanes sp. during fermentation and are released into the culture medium, to a process for isolating the lipopeptides from the culture medium and purifying them, to the use of the lipopeptides as pharmacologically active substances, in particular against Gram-positive bacteria, and to Actinoplanes sp. DSM 7358 for producing the abovementioned lipopeptides.

Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof

The present invention relates to a novel lantibiotic having the formula NH.sub.2 --R-actagardine, where NH.sub.2 --R is the radical of the amino acid alanine, which is formed by the microorganism Actinoplanes liguriae, DSM 11797 or Actinoplanes garbadiensis, DSM 11796 during fermentation, chemical derivatives of the lantibiotic, a process for its preparation and the use of the lantibiotics as pharmaceuticals.

Lantibiotic related to actagardine, and processes for the preparation

Growing community of inventors

Rödermark, Germany

Joachim Wink